Prognostic effects of novel agents on cytogenetic abnormalities of multiple myeloma
10.3760/cma.j.issn.1009-9921.2015.02.015
- VernacularTitle:新药对分子遗传学异常的多发性骨髓瘤患者预后的影响
- Author:
Wenjie XIONG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Cytogenetic abnormalities;
Noval agents
- From:
Journal of Leukemia & Lymphoma
2015;24(2):122-125
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a heterogeneous disease with certain cytogenetic abnormalities [1q21 gains,t(4;14),del 17p] associated with worse outcome.The extensive use of thalidomide,lenalidomide and bortezomib has dramatically improved the outcome for patients with MM and some cytogenetic abnormalities.It is also widely proved that bortezomib can partly overcome the harmful affects of t (4;14).However,till now,there are many controversies about the effects of some novel agents worked on certain cytogenetic abnormalities.In this review,the effects of novel agents in cytogenetic abnormalities were summaried to provide new information on clinical treatment of this disease.
